Arctic Bioscience AS

Arctic Bioscience AS Forward P/E

The Forward P/E Ratio of Arctic Bioscience AS (ABS.OL) as of Oct 17, 2026 is -2.19. In the previous year, Forward P/E Ratio was -1.88 — a change of 16.84% (lower).

Forward P/E

-2.19

YoY

16.84%

Last updated:

Forward P/E Ratio of Arctic Bioscience AS is 2025 -2.19 . Forward P/E Ratio of Arctic Bioscience AS was 2024 -1.88 . It decreases by 16.84% lower compared to the previous year.

The Arctic Bioscience AS Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-52.65 NOK
Jan 1, 2019
-22.57 NOK
Jan 1, 2020
-3.99 NOK
Jan 1, 2021
-2.11 NOK
Jan 1, 2022
-2.65 NOK
Jan 1, 2023
-1.98 NOK
Jan 1, 2024
-1.88 NOK
Jan 1, 2025
-2.19 NOK
The Arctic Bioscience AS Forward P/E history
YEARForward P/EYoY
-2.19+16.84%
-1.88-5.05%
-1.98-25.25%
-2.65+25.14%
-2.11-46.94%
-3.99-82.34%
-22.57-57.14%
-52.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arctic Bioscience AS Stock analysis

What does Arctic Bioscience AS do? Arctic Bioscience AS is a biotechnology company headquartered in Orsta, Norway, operating within the Health Care sector. The company focuses on the development, manufacturing, and marketing of marine ingredients derived from herring roe. It completed its initial public offering (IPO) on February 24, 2021. Arctic Bioscience aims to provide effective and healthy therapeutic solutions for individuals with autoimmune disorders through marine membrane lipids. The company is developing HRO350, an investigational drug candidate intended for the treatment of mild-to-moderate psoriasis. Its product portfolio includes Romega, a dietary supplement containing omega-3 fatty acids sourced from herring roe in capsule form, as well as herring caviar oil and herring caviar protein offered to business customers. The company operates through three subsidiaries: Arctic Nutrition AS, Romega AS, and Arctic Biopharma AS. Arctic Bioscience AS is listed on the Oslo Stock Exchange under the ticker symbol ABS.OL and holds the ISIN NO0010859580. The company's activities are centered around leveraging marine resources for health-related applications, with a focus on innovative biotechnology solutions for autoimmune conditions and skin health. Arctic Bioscience AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arctic Bioscience AS stock

Forward P/E Ratio of Arctic Bioscience AS is -2.19 in 2025.

Forward P/E Ratio of Arctic Bioscience AS changed from -1.88 to -2.19, representing a 16.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Arctic Bioscience AS since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Arctic Bioscience AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Arctic Bioscience AS

All Key Metrics — Arctic Bioscience AS